1、1IMAGINE IF THE NEXT PAGE FEATURED EUROPE AS THE WORLD LEADER IN LIFE SCIENCES.A Competitiveness Strategy for European Life Sciences2Why it matters:The life sciences sector is one of Europes most important strategic assets,delivering innovative medicines and vaccines that are fundamental to the long

2、-term health and security of EU citizens.In recent decades we have seen HIV turned from a death sentence to a condition that can be managed,huge advances in cancer care transforming survival rates,hepatitis C can now be cured in 95%of patients,and there are new tools to stem the tide of the obesity

3、epidemic and manage cardio-vascular disease.The sector contributes more to the EUs trade balance than any other.Research-based pharmaceutical companies invest a greater percentage of their revenue back into research and development than any other sector and act as a catalyst for cutting-edge technol

4、ogies like biotech,AI and digital health.The pharmaceutical industry is responsible for about 21%of global research expenditure.It directly employs around 900,000 people across the region and indirectly generates over 2.5 million jobs.At the same time,Europes life science eco-system is facing intens

5、e pressure from the US and China where more ambitious,dedicated strategies are driving growth.Over the last two decades 25%of Europes share of global R&D investment has been redistributed to other regions of the world.Similarly,our share of global clinical trials has fallen from 25.6%to 19.3%in the

6、last decade.European biotechs are only able to access around 20%of the finance that their US counterparts can and today,nearly three-quarters of European science graduates choose to remain in the US in hubs like Boston and San Francisco after completing their doctorates.Why now?Against a backdrop of